BIVI vs NVNI Comparison

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Nvni Group Ltd, through its existing subsidiary companies, operates business-to-business software-as-a-service (B2B SaaS) products in Brazil, serving a diversified customer base of small and mid-sized enterprises across vertical markets. The Group's core business activity is providing a SaaS platform model focused on the software delivery method of cloud-based software applications to its customers. The Group generates revenues and profits from SaaS platform subscription services, data analytics services, set-up and other services. The Group has a single operating and reportable segment, multi-vertical SaaS solution model. The Group operates and generates revenue from Brazil.